Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

In the original publication, the name of the fourth author should be: Takafumi Sangai and his affiliation should be.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research